For primary hyperlipidemia. ANDA 210316, held by Alkem Labs Ltd. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 210316 (Colesevelam Hydrochloride), held by Alkem Labs Ltd, was first approved by FDA on May 6, 2019, with 1 approved supplement and 0 published complete response letters.
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heteroz ygous familial hypercholesterolemia (HeFH). Limitations of Use: Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. The effect on cardiovascular morbidity and mortality has not been determined. Not studied in type 2 diabetes with a dipeptidyl peptidase 4 inhibitor. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 6, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride3.75GM/PACKET · for suspension;oral | Colesevelam Hydrochloride | Rx |
| Mar 16, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 6, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters